April 3, 2018 / 12:48 PM / 7 months ago

BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America

1 Min Read

April 3 (Reuters) - Puma Biotechnology Inc:

* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA

* ‍PUMA WILL RECEIVE AN UPFRONT PAYMENT AS WELL AS POTENTIAL REGULATORY AND COMMERCIAL MILESTONE PAYMENTS TOTALING UP TO $34.5 MILLION​

* DIGIT ROYALTIES ON NERLYNX SALES IN LATIN AMERICA

* DEAL FOR PINT PHARMA TO COMMERCIALIZE NERLYNX IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, MEXICO AND REST OF LATIN AMERICA​

* PINT PHARMA WILL BE RESPONSIBLE FOR COMMERCIALIZING NERLYNX IN LATIN AMERICA Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.